Please login to the form below

Not currently logged in
Email:
Password:

Cell Design Labs

This page shows the latest Cell Design Labs news and features for those working in and with pharma, biotech and healthcare.

Roche's O’Day swaps big pharma for big biotech

Roche's O’Day swaps big pharma for big biotech

Among Gilead's moves is a shift into immuno-oncology via the acquisition of CAR-T specialist   Kite Pharma for almost $12bn and smaller player Cell Design Labs, a $3bn agreement

Latest news

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    Celgene is in talks with Juno Therapeutics about a possible takeover deal, right after cutting a $7bn deal to buy Impact Labs, according to media reports. ... Gilead followed the Kite deal with a smaller buyout of CAR-T firm Cell Design Labs last month.

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    Just a few months after shelling out $12bn to buy CAR-T specialist Kite Pharma, Gilead Sciences is boosting its position in the category with a $567m swoop on Cell Design ... for a green light from the FDA for Kymriah (tisagenlecleucel) as a treatment

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells). ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics